MetaCap

Artiva Biotherapeutics (ARTV) vs Century Therapeutics (IPSC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Century Therapeutics (IPSC) has outperformed Artiva Biotherapeutics (ARTV) over the past year, gaining 137.8% versus a gain of 20.8%. Century Therapeutics is the larger company by market cap ($211.6 million vs $186.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%IPSC+137.76%
+525%+249%-27%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%IPSC-53.40%
+38%-28%-94%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus IPSC key metrics
MetricARTVIPSC
Share price$3.78$1.17
Market cap$186.85M$211.56M
1-day change-1.31%-11.74%
YTD return-11.89%+17.09%
1-year return+20.77%+137.76%
5-year return—-93.23%
EPS (TTM)$-2.85$-0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$109.16M
Revenue growth (YoY)-100.00%+1556.76%
Net income (latest FY)$-83.86M$-9.58M
Operating margin—-15.82%
Net margin—-8.78%
52-week high$14.53$3.04
52-week low$2.96$0.48
Distance from 52-week high-73.98%-61.68%
Analyst consensusbuybuy
Avg. price target upside+448.94%+307.73%
Average volume792.26K759.69K
Shares outstanding49.43M181.60M
Employees13478
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IPSC has outperformed ARTV by 117.0 percentage points over the past year.
  • Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs -100.00%).

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Century Therapeutics

IPSC stock →

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees

ARTV vs IPSC FAQ

Which is bigger, Artiva Biotherapeutics or Century Therapeutics?

Century Therapeutics (IPSC) is larger, with a market capitalization of $211.56M compared with $186.85M for Artiva Biotherapeutics (ARTV).

Which stock has performed better over the past year, ARTV or IPSC?

IPSC returned +137.76% over the past 12 months, compared with +20.77% for ARTV (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Century Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons